RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | £7,448 | £4,531 | £2,937 | £3,494 |
| - Cash | £3,567 | £3,779 | £3,931 | £493 |
| + Debt | £1,029 | £1,176 | £389 | £445 |
| Enterprise Value | £4,910 | £1,928 | -£605 | £3,446 |
| Revenue | £2,589 | £1,524 | £1,397 | £794 |
| % Growth | 69.9% | 9.1% | 75.9% | – |
| Gross Profit | £1,903 | £1,091 | £1,100 | £431 |
| % Margin | 73.5% | 71.6% | 78.7% | 54.3% |
| EBITDA | -£442 | £843 | -£398 | -£1,175 |
| % Margin | -17.1% | 55.3% | -28.5% | -148% |
| Net Income | -£635 | £636 | -£430 | -£1,010 |
| % Margin | -24.5% | 41.7% | -30.8% | -127.2% |
| EPS Diluted | -0.01 | 0.019 | -0.013 | -0.046 |
| % Growth | -154% | 247.7% | 71.9% | – |
| Operating Cash Flow | £4 | -£219 | -£445 | -£904 |
| Capital Expenditures | -£27 | -£35 | -£13 | -£42 |
| Free Cash Flow | -£23 | -£254 | -£458 | -£946 |